- Home
- MTNB
as 09-05-2025 4:00pm EST
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | BEDMINSTER |
| Market Cap: | 7.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $4.25 | Next Earning Date: | 08-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Matinas Biopharma Holdings Inc. News
MTNB Breaking Stock News: Dive into MTNB Ticker-Specific Updates for Smart Investing
MT Newswires
6 months ago
Matinas BioPharma Chairman Eric Ende Resigns
GlobeNewswire
6 months ago
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
7 months ago
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
GlobeNewswire
7 months ago
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
GlobeNewswire
8 months ago
Matinas BioPharma Receives NYSE Noncompliance Notice
MT Newswires
10 months ago
Top Midday Decliners
GlobeNewswire
10 months ago
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
GuruFocus.com
10 months ago
Highbridge Capital Management's Strategic Acquisition in Matinas BioPharma
Compare MTNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTNB Matinas Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.